← All trials
NCT04872686
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 10, 2021
- Primary completion
- May 31, 2021
- Completion date
- May 31, 2021
- First posted
- May 4, 2021
- Last posted
- May 13, 2021
- Enrollment
- 798
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bangladesh Reference Institute of Chemical MeasurementsLead sponsor
- Bangladesh Reference Institute of Chemical Measurements (BRICM)Sponsor investigator
- Bangladesh Reference Institute of Chemical Measurements (BRICM)Collaborator
- Dhaka Medical CollegeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.